Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4281 trials
Conditions Gastric Cancer, Esophageal Cancer, Cervi...
Phase Not Applicable
Enrollment 10
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This trial plans to enroll many patients with advanced solid tumors to complete GK01 cell transfusion, including but not limited to advanced gastric cancer, esophageal cancer, cervical cancer, triple-negative breast cancer, and non-small cell lung cancer. For patients with advanced solid tumors eligible for inclusion, autologous tumor-reactive T cells (experimental drug GK01) were cultured and prepared, and a certain dose of GK01 cells was given according to the cell transfusion plan, and the safety and tolerability of the patients after transfusion were observed. Exploratory evaluation of pharmacokinetic/pharmacodynamic profiles following reinfusion and initial evaluation of efficacy of investigational drug GK01 cells according to RECIST 1.1 criteria.

Design

Study type: Observational Observational model: Case Only Time perspective: Prospective

Interventions / Regimen

  • Biological: TCR T-cells — The strengthened T cells are re-infused into the patient to achieve the killing effect

Primary Outcomes

  • safety and tolerability (From enrollment to the end of follow-up visit at 22weaks or more)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2023-07-19
Completion: 2026-11-19
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 10 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Beijing Geekgene Technology Co., LTD
Contact Information
Study Contact:
Yi Zhang, Doctor
86+15138928971
yizhang@zzu.edu.cn
Ge Zhang
0086+13633861412
zhangg@geekgene.cn
Yi Zhang, Doctor
626-491-5096
yizhang@zzu.edu.cn
First Affiliated Hospital of Zhengzhou University
Interventions
  • Biological: TCR T-cells — The strengthened T cells are re-infused into the patient to achieve the killing effect
Study Locations (1 sites)
First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450052 China
Eligibility Criteria
Inclusion Criteria: * Participants who meet all of the following criteria are eligible for admission to the study: 1. 18≤ age ≤75 years old, male or female; 2. Patients with incurable advanced gastric cancer, esophageal cancer, cervical cancer, triple-negative breast cancer, non-small cell lung cancer, and other malignancies who have failed standard treatment (standard treatment failure is defined as those treated according to the 2022 CSCO Guidelines and whose tumor efficacy is assessed as disease progression (PD) or tumor recurrence or inability to tolerate existing treatment options); 3. There are tumor tissues or cancerous exudative thoracoabdominal fluid that can be used to isolate TRTs: the total volume of the solid tissue taken must be \> 0.5cm3 or the weight must be \>0.5g, the cancerous exudative thoracoabdominal fluid taken should contain at least 5×10\^8 total cells, and the lesions taken have not been treated with oncolytic virus. 4. There is at least one measurable lesion (according to RECIST1.1 criteria) even after TRTs sampling/puncture biopsy; 5. ECOG score 0-1; 6. The expected survival period is greater than 3 months; 7. Sufficient hematology and end-organ function, as defined by the following laboratory test results, should be completed within 14 days prior to TRTs tumor tissue collection: 1. Blood routine: white blood cell count ≥2.5×10\^9/L; Absolute neutrophil count (ANC) ≥1.5×10\^9/L; Absolute lymphocyte count (ALC) ≥1.0×10\^9/L; Platelet (PLT) ≥80×10\^9/L; Hemoglobin (HGB) ≥90g/L; 2. Coagulation function: International standardized ratio of prothrombin time (INR) ≤1.5×ULN; Partial prothrombin time (APTT) ≤1.5×ULN, unless anticoagulant therapy has been received within the previous 7 days; 3. Renal function: serum creatinine ≤1.5mg/dL (or 132.6μmol/L) or creatinine clearance ≥60mL/ min; 4. Liver function: aspartate aminotransferase (AST/SGOT) ≤3×ULN; Alanine transaminase (ALT/SGPT) ≤3×ULN; Total bilirubin (TBIL) ≤1.5×ULN; Note: In patients with liver metastasis or primary liver tumor, aspartate and alanine aminotransferase should be ≤5×ULN; For patients with a history of Gilbert syndrome or suspected Gilbert syndrome, total bilirubin (TBIL) should be ≤3×ULN; 5. Urine routine: urinary protein \<2+, or 24-hour urinary protein quantity \<1g; 6. Left ventricular ejection fraction (LVEF) ≥50% by echocardiography; 7. Pulmonary function tests with FEV1\>60% or FEV1/FVC\>0.7; 8. Blood oxygen saturation ≥ 93%. 8. Women of childbearing age who have a negative urine pregnancy test during screening and baseline and agree to use highly effective contraception for at least 1 year after the infusion; Male subjects whose partners are fertile must agree to use effective contraceptive methods and refrain from sperm donation for at least 1 year after the infusion; 9. No absolute or relative contraindications to surgery or puncture; 10. Any treatment for malignant tumors, including radiotherapy, chemotherapy, endocrine therapy, targeted therapy, tumor embolization, or Chinese medicine/herbal therapy with anti-tumor indications, must be discontinued 7 days before TRT sampling; 11. Sign a written informed consent (ICF) voluntarily, and have good compliance with the protocol requirements for visits or planned visits and other relevant research procedures. Exclusion Criteria: * Subjects who meet any of the following criteria will not be eligible to participate in this clinical trial: 1. Prior allergy to cyclophosphamide, fludarabine and interleukin-2 contraindications or to any component of the infusion product formulation or to other drugs to be used during the study (antibiotics, human serum albumin, dextran 40, etc.); 2. Any NCI CTCAE5.0 immune-related adverse reaction (irAE) grade \>3 that has been permanently discontinued during any previous immunotherapy; 3. Patients with prior primary immunodeficiency and active autoimmune disease; 4. Previous history of organ allotransplantation, allogeneic stem cell transplantation and kidney replacement therapy; 5. Patients with current or past irreversible interstitial lung disease (except those caused by radiotherapy); 6. Combined with 2 or more malignant tumors; (Except for the following cases: malignant tumors that have been cured, such as non-melanoma skin cancer and in situ cervical cancer, bladder cancer, breast cancer, thyroid cancer, etc. that have survived more than 5 years without disease.) 7. Uncontrolled co-morbidity includes, but is not limited to, uncontrolled hypertension (systolic blood pressure ≥160mmHg and/or diastolic blood pressure ≥100mmHg) even after standard treatment, or any unstable cardiovascular and cerebrovascular disease, including transient ischemic attack, cerebrovascular accident, myocardial infarction, and unstable angina pectoral, that has occurred in the 6 months prior to treatment induction; Congestive heart failure rated III or IV by the New York Heart Association (NYHA); Ejection fraction \< 50%; Severe heart rhythm or conduction abnormalities, such as ventricular arrhythmias requiring clinical intervention, degree II-III atrioventricular block, etc. Electrocardiogram results show clinically significant abnormalities, or QTcF≥450ms (if the first examination is abnormal, the interval of at least 5 minutes, retest twice, using the comprehensive result/average value to judge eligibility); 8. Patients with esophageal or gastric varices that require immediate intervention (such as ligation or sclerotherapy) or are considered by the investigator or gastroenterologist or hepatologist to be at high risk of bleeding, have evidence of portal hypertension (including splenomegalysis on imaging), or have a history of varicose bleeding must undergo endoscopic evaluation within 3 months prior to enrollment; 9. Uncontrolled metabolic disorders, such as in patients with diabetes, or other non-malignant organ or systemic disease or cancer secondary reactions that can lead to higher medical risk and/or uncertainty in the evaluation of survival; 10. Hepatic encephalopathy, hepatorenal syndrome or Child-Pugh grade C or more severe cirrhosis, liver failure; 11. Clinically uncontrollable third space effusion, such as pleural fluid and ascites that could not be controlled by drainage or other methods before enrollment; 12. Combined with other serious organic disease or mental illness; 13. Patients with central nervous system metastasis; 14. Uncontrolled systemic active infection; 15. Receive vaccination within 2 months before signing the informed consent, or plan to receive vaccination during the study; 16. Currently or within 30 days before signing the informed consent to participate in clinical trials of other drugs or biotherapeutics, except cell therapy that has been fully metabolized; 17. have used within 4 weeks prior to the treatment, or have concomitant disease or active autoimmune disease that the investigator determined required the use of glucocorticoids or other immunosuppressive drugs during the trial period, excluding local percutaneous absorption of glucocorticoids (i.e., no more than 5 mg/ day of prednisone or equivalent doses of other glucocorticoids); 18. Surgical treatment, interventional therapy, radiotherapy, chemotherapy and immunotherapy for the studied disease were performed within 2 weeks before the treatment; 19. HIV positive, serological test positive for syphilis, or clinically active hepatitis B or C, including carriers of the virus (for hepatitis B, HBsAg positive persons should be excluded; For hepatitis C, HCVAB-positive patients need to be excluded); 20. Women who are breastfeeding during pregnancy or lactation; 21. Poor compliance due to physiological, family, social, geographical and other factors, unable to cooperate with the study protocol and follow-up plan; 2
Conditions Multiple Sclerosis, Hypertension
Phase NA
Enrollment 80
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this study is to determine if 12 weeks of cycling exercise training at home will improve three parameters: 1) blood pressure, 2) cognition, and 3) walking ability among persons with multiple sclerosis who have high blood pressure, when compared to a group that engages in a 12-week home-based stretching program. The main questions this study aims to answer are: 1. Can home-based cycling exercise training improve blood pressure by increasing blood vessel dilation in people with multiple sclerosis? 2. Can cycling exercise training improve cognition and walking mobility in people with multiple sclerosis by improving blood pressure? The investigators will compare home-based cycling training to stretching to see if cycling training improves cognition, walking mobility, blood pressure, and fitness in people with multiple sclerosis. Participation in this study will take 13-14 weeks, with participants being randomized (like flipping a coin, a 50-50 chance of being in either group) to the home-based cycling training or the stretching group. All participants will be asked to * Visit the laboratory two times, one before the beginning of the intervention (home-base training and stretching group) and one at the end of the intervention. * During visits, participants will complete tests related to cognition, walking mobility, blood pressure and fitness.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Behavioral: Home-based aerobic training — The aerobic training will focus on large, dynamic movements of the lower extremities using leg cycling ergometry on an upright cycle ergometer installed in the participant's homes and will progress in duration (10-40 minutes) and intensity (50-70% VO2 peak) over the 3-month intervention period. All participants will start exercise at 50% of VO2peak for 10-min as determined by the exercise test, for the first week, to individualize the exercise prescription. Progression will initially target duration with weekly progressions of 5 min to 30 min of exercise, followed by progression of intensity by 5% per week until 70% is attained, based on patient tolerance of the increased work.

Primary Outcomes

  • Information processing speed (Baseline, pre-intervention/BICAMS; Within 5 days after completion of the training intervention/BICAMS)
  • Timed 25-Foot Walk (Baseline, pre-intervention/25-Foot Walk; Within 5 days after completion of training intervention/ 25-Foot Walk)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-04-15
Completion: 2027-08
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 80 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Massachusetts, Boston
Collaborators: University of Illinois at Chicago, University of Alabama at Birmingham
Principal Investigators:
  • Bo Fernhall, PhD (PRINCIPAL_INVESTIGATOR) - University of Massachusetts, Boston
  • Tracy Baynard, PhD (PRINCIPAL_INVESTIGATOR) - University of Massachusetts, Boston
Contact Information
Study Contact:
Tracy Baynard, PhD
2178404493
tracy.baynard@umb.edu
Joao L Maroco, MS
7738933897
joao.maroco001@umb.edu
Interventions
  • Behavioral: Home-based aerobic training — The aerobic training will focus on large, dynamic movements of the lower extremities using leg cycling ergometry on an upright cycle ergometer installed in the participant's homes and will progress in duration (10-40 minutes) and intensity (50-70% VO2 peak) over the 3-month intervention period. All participants will start exercise at 50% of VO2peak for 10-min as determined by the exercise test, for the first week, to individualize the exercise prescription. Progression will initially target duration with weekly progressions of 5 min to 30 min of exercise, followed by progression of intensity by 5% per week until 70% is attained, based on patient tolerance of the increased work.
Study Locations (1 sites)
UMass Boston, Boston, Massachusetts 02125 United States
Eligibility Criteria
Inclusion Criteria: * Persons with confirmed multiple sclerosis diagnosis with Expanded Disability Status Scale scores of 4-6.5, characteristic of 2nd stage of multiple sclerosis; * Hypertension defined as elevated, or Stage 1 or 2, as per the 2017 American Heart Association guidelines (brachial systolic blood pressure \> 120 mmHg or brachial diastolic blood pressure \> 80 mmHg) * Persons who are physically inactive (less than 60 min/wk of physical activity); * Persons with body mass index \< 40 kg/m2; * Persons who are not confined to a wheel chair; * Multiple sclerosis relapse in the past 30 days; * People with stable pharmacotherapy. Exclusion Criteria: * People with additional cardiovascular comorbidities; * People with type 1 diabetes mellitus; * Physician disapproval to participating in the study; * Space constraints to fit a cycle ergometer at the home of prospective participants.
Conditions Premenstrual Dysphoric Disorder
Phase NA
Enrollment 164
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Premenstrual dysphoric disorder (PMDD) is a debilitating cyclic mental disorder affecting about 2-5% of women of reproductive age. PMDD is characterised by recurring emotional, behavioural, cognitive, and somatic symptoms that arise during the luteal (premenstrual) phase of the menstrual cycle and remit shortly after the onset of menses. Although pharmacological interventions are available, many women experience residual symptoms, discontinue treatment or refrain from them because of side effects. Therefore, non-pharmacological treatment options are needed. Preliminary evidence suggests that internet-delivered cognitive behavioural therapy (ICBT) is a promising candidate, but further research is warranted. Also, there is room for treatment improvement. Specifically, it has been suggested that components targeting emotional and interpersonal dysregulation should be incorporated into CBT for PMDD. The current study aims to assess the effects of an ICBT intervention for PMDD incorporating skills training in emotion regulation and interpersonal effectiveness in a randomised controlled trial (RCT).

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Single

Interventions / Regimen

  • Behavioral: Therapist-guided internet-delivered cognitive behavioural therapy — The intervention consists of 8 weeks of therapist-guided self-help ICBT.

Primary Outcomes

  • Group differences in premenstrual symptoms and their impact on everyday life during the luteal phase from baseline to post-treatment (Baseline to post-treatment (daily ratings over two menstrual cycles [ca 56 days] starting 8 weeks after baseline). Follow-up assessments at 6 and 12 months post-treatment (daily ratings one cycle [ca 28 days] beginning 6 and 12 months post-treatment).)
  • Group differences in PMDD-related psychological and functional impairment during the luteal phase from baseline to post-treatment (Baseline to post-treatment (first luteal phase after treatment, i.e., 8-10 weeks after baseline). Follow-up assessments at 6 and 12 months post-treatment. All assessements will be collected during luteal phase.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-07-14
Completion: 2028-07
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 164 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Uppsala University
Collaborators: Friedrich-Alexander-Universität Erlangen-Nürnberg, Utah State University, Linkoeping University
Contact Information
Study Contact:
Johanna Motilla Hoppe, PhD
+46735252205
johanna.motilla_hoppe@uu.se
Monica Buhrman, Associate Professor
+46 18 471 2126
Monica.Buhrman@psyk.uu.se
Johanna Motilla Hoppe, PhD
+46735252205
johanna.motilla_hoppe@uu.se
Uppsala university
Interventions
  • Behavioral: Therapist-guided internet-delivered cognitive behavioural therapy — The intervention consists of 8 weeks of therapist-guided self-help ICBT.
Study Locations (1 sites)
Uppsala university, Uppsala, Uppsala County 75656 Sweden
Eligibility Criteria
Inclusion Criteria: 1. PMDD diagnosis according to DSM-5 2. Menstrual cycle length between 23-34 days, i.e., 5-8 cycles in the last six months 3. Sufficient proficiency in Swedish to comprehend the treatment materials 4. Access to computer/tablet/mobile phone with internet connection Exclusion Criteria: 1. Breastfeeding or pregnancy during the previous three months 2. Initiation of or change in treatment with antidepressants, benzodiazepines, contraceptives, or hormones during the last three months 3. Current or history of a gynaecological disease (e.g., endometriosis, polycystic ovary syndrome) that may confound the results 4. Ongoing or previous psychological treatment for premenstrual disorders 5. Severe mental disorders that may interfere with the person's ability to complete the treatment or complicate the interpretation of results, e.g., psychosis, bipolar disorder, severe eating disorder, or severe depression 6. Elevated suicide risk (e.g., recurrent active suicidal ideation, current suicide plans, previous suicide attempts).

Non-invasive Tools for PSVD Diagnosis

NCT06500403
Recruiting
Conditions Non-Cirrhotic Portal Hypertension, Porto...
Phase Not Applicable
Enrollment 1000
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Patients treated with platinum-based chemotherapy drugs have the probability of developing PSVD. The diagnosis of PSVD depends on liver biopsy. In addition, the level of portal vein pressure has guiding value in the diagnosis and prognosis of PSVD. Many studies have shown that liver and spleen stiffness have high accuracy in diagnosis and prognosis. The purpose of this study is to evaluate the efficacy of the combination of liver and spleen stiffness in the diagnosis of PSVD and to search for effective biomarkers for the diagnosis of PSVD through a single-center, prospective, observational study.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Diagnostic Test: liver and stiffness measurement — liver and spleen stiffness measurement are non-invasive tools for evaluation of cirrhosis and portal hypertension

Primary Outcomes

  • Searching for valid non-invasive tools for the diagnosis of PSVD (2 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2024-02-28
Completion: 2029-12-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 1000 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Nanfang Hospital, Southern Medical University
Principal Investigators:
  • Xiaofeng Zhang (PRINCIPAL_INVESTIGATOR) - Nanfang Hospital, Southern Medical University
Contact Information
Study Contact:
Xiaofeng Zhang
+8618565552050
1282614092@qq.com
Xiaofeng Zhang
+8618565552050
1282614092@qq.com
Nanfang hospital, Southern Medical Uiversity
Interventions
  • Diagnostic Test: liver and stiffness measurement — liver and spleen stiffness measurement are non-invasive tools for evaluation of cirrhosis and portal hypertension
Study Locations (1 sites)
Nanfang hospital, Southern Medical Uiversity, Guangzhou, Guangdong 510080 China
Eligibility Criteria
Inclusion Criteria: 1. Received platinum chemotherapy for organ tumors; 2. Ages 18-80; 3. sign the informed consent voluntarily. Exclusion Criteria: 1. Liver pathology suggested cirrhosis; 2. Underwent liver transplantation; 3. Combined with hepatocellular carcinoma exceeding Milan criteria; 4. Complicated with severe heart, kidney, or lung failure; 5. Pregnant or lactating women; 6. Data is seriously missing; 7. Patients were judged not suitable for participation in this study by the researchers.
Conditions Major Depressive Disorder, Treatment Res...
Phase NA
Enrollment 12
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Major depressive disorder (MDD) is a complex and severe mental illness, characterized by multiple symptoms, and is a leading cause of non-fatal health loss. Despite this, approximately 30% of patients do not respond to standard pharmacological or psychological treatments. Currently, we lack objective brain-based biomarkers to differentiate between natural mood fluctuations and situations requiring intervention. To address this issue, we employed a novel electrophysiology recording device and applied deep brain stimulation (DBS) to 12 MDD patients. Our study aims to use long-term invasive neural signal collection and machine learning techniques to reveal the complex relationship between these signals and depressive symptoms. By applying advanced machine learning algorithms, our goal is to establish highly accurate prediction models to identify biomarkers associated with the occurrence and progression of depression. The research will focus on the spatiotemporal features of neural signals and build personalized depression decoding models based on individual differences through the integration and analysis of large-scale data. By delving into the information contained in neural signals, we hope to contribute to the development of personalized treatment approaches for depression.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Procedure: Deep Brain stimulation — All subjects will receive bilateral surgical implantation of DBS system.

Primary Outcomes

  • Identifying an electrophysiological biomarker of MDD (30 days)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-08-03
Completion: 2026-12-03
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 12 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: West China Hospital
Collaborators: Beijing Pins Medical Co., Ltd
Contact Information
Study Contact:
wei wang, M.D.
+86 13808170699
wcnsww@163.com
Botao Xiong, M.D.
+86 13927498309
Botao-x@foxmail.com
Botao Xiong, M.D.
13927498309
Botao-x@foxmail.com
West CHina Hospital,Sichuan University
Interventions
  • Procedure: Deep Brain stimulation — All subjects will receive bilateral surgical implantation of DBS system.
Study Locations (1 sites)
West CHina Hospital,Sichuan University, Chengdu, Sichuan 610041 China
Eligibility Criteria
Inclusion Criteria: * 1\) Participants in the study should sign a research informed consent form before starting any research-related procedures; 2) Participants must be between the ages of 16 and 30, regardless of gender; 3) Diagnosed with Major Depressive Disorder (MDD) according to the diagnostic criteria in the DSM-V; 4) Participants must have medical records of their current depressive episode that has lasted for ≥2 years, or recurrent episodes, with a minimum of 4 episodes (with the current episode lasting at least 1 year); 5) Have previously failed at least 3 courses of adequate antidepressant therapy, using 2 or more different classes of antidepressants; and have refused, been unable to tolerate, or found electroconvulsive therapy (ECT) to be ineffective; 6) Participants must have a HAMD-17 score of ≥20 or a MADRS score of ≥25; 7) Participants must be able to communicate effectively, and the participant and their legal guardian must sign a written informed consent form. Exclusion Criteria: * 1\) Participants with bipolar disorder, schizoaffective disorder, schizophrenia, or other psychotic disorders; 2) Severe personality disorders; 3) Severe physical diseases or organic brain diseases; 4) Participants with alcohol or substance abuse and dependence diagnosed within 1 year prior to screening according to DSM-IV criteria; 5) Participants with surgical contraindications, such as significant comorbid medical conditions or inability to discontinue anticoagulation medications; 6) Structural imaging abnormalities evident on MRI performed within 1 year prior to screening; 7) MRI contraindications (excluding DBS implantation or the device itself); 8) Pregnant or breastfeeding; 9) Participants who are enrolled in another study unrelated to the current study; 10) Any condition that may currently or potentially endanger the participant's safety or preclude their successful participation in the study (family support, medical, psychological, social, or geographic factors).
Conditions Asthma; Eosinophilic
Phase PHASE3
Enrollment 418
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Phase III clinical study of SIM0718 asthma

Design

Study type: Interventional Phases: Phase3 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Quadruple

Interventions / Regimen

  • Drug: SIM0718 injection — Dosage form: injection Specification: 300mg/2ml/bottle Dosage: A loading dose of 600 mg is injected subcutaneously on day 1, followed by 300 mg SIM0718 subcutaneously every two weeks. Duration of medication: 52 weeks
  • Drug: SIM0718 injection of placebo — Dosage form: injection Specification: 2ml/bottle Dosage: 4ml subcutaneously on day 1, followed by 2ml of placebo subcutaneously every two weeks. Duration of medication: 52 weeks

Primary Outcomes

  • Annualized rate of severe asthma exacerbation events (52 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE3
Status: Recruiting
Start Date: 2024-06-23
Completion: 2027-09-30
Eligibility
Age: 12 Years and older
Sex: ALL
Volunteers: false
Enrollment: 418 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Simcere Pharmaceutical Co., Ltd
Principal Investigators:
  • L I hong zhuang (STUDY_DIRECTOR) - Simcere Pharmaceutical Co., Ltd
Contact Information
Study Contact:
Yi Wang
+8615805160455
wangyi4@simcere.com
wei wang
Ting yang, doctor
China Japan Friendship Hospital
Interventions
  • Drug: SIM0718 injection — Dosage form: injection Specification: 300mg/2ml/bottle Dosage: A loading dose of 600 mg is injected subcutaneously on day 1, followed by 300 mg SIM0718 subcutaneously every two weeks. Duration of medication: 52 weeks
  • Drug: SIM0718 injection of placebo — Dosage form: injection Specification: 2ml/bottle Dosage: 4ml subcutaneously on day 1, followed by 2ml of placebo subcutaneously every two weeks. Duration of medication: 52 weeks
Study Locations (1 sites)
China Japan Friendship Hospital, Beijing, Beijing Municipality 100000 China
Eligibility Criteria
Inclusion Criteria: * Age 12 to 75 years, weight ≥ 40 kg, diagnosed with asthma for at least 12 months; * Currently receiving medium- to high-dose inhaled corticosteroids (ICS) in combination with 1 or 2 control medications and have been on a stable dose for at least 28 days prior to randomization; * Pre-bronchodilator (trough) FEV1 ≤ 80% of predicted normal for adults and ≤90% of predicted normal for adolescents ; * Positive bronchodilator response within 12 months prior to randomization or during the screening period; * Asthma Control Questionnaire (ACQ-5) score ≥ 1.5; * At least one severe asthma exacerbation within 12 months prior to the screening visit and no occurrence within 28 days prior to randomization; * Based on the investigator judgment, the subject demonstrates acceptable inhaler, peak flow meter, and spirometry techniques; * Compliance with usual asthma controller use ≥ 80% based on the patient diary in 7 days prior to dosing; * Voluntarily participate in this clinical study and sign the informed consent form and be able to comply with the clinical visit schedule and study-related procedures; * Female subjects of childbearing potential who are sexually active with non-sterilized male partners, male subjects, and their female partners of childbearing potential agree to use adequate and effective contraception throughout the study; Exclusion Criteria: * Current respiratory disease that may impair lung function as judged by the investigator; * Diagnosis of helminth parasitic infection within 24 weeks prior to randomization and who have not received or have not responded to standard therapy; * Within 28 days prior to randomization, with acute or chronic infection; or have a severe viral infection; * Has a known or suspected history of immunosuppression or frequent, recurrent, or long-term infection; * History of active tuberculosis; or untreated latent tuberculosis or tuberculosis not receiving standard treatment, unless the investigator judges that the patient has been adequately treated; * People with hepatitis B, hepatitis C, or HIV infection; * History of malignancy; * Major surgery within 8 weeks prior to signing the informed; * Bronchial thermoplasty within 12 months prior to randomization; * Treatment of systemic glucocorticoid during 4 weeks prior to signing informed to randomization; * Previous use or ongoing use of systemic immunosuppressants or biologics for the treatment of autoimmune or inflammatory diseases in 8 weeks or 5 half-lives prior to randomization; * Within 16 weeks or 5 half-lives prior to randomization, received a biologic agent with the same therapeutic purpose; * Participated in an interventional clinical trial of any drug or medical device within 3 months or 5 half-lives prior to randomization; * Poor response to or intolerance to prior anti-IL-4Rα antibody therapy; * Within 3 months prior to randomization, received specific immunotherapy; * Receipt of intravenous human immunoglobulin (IVIG) or blood products within 30 days prior to randomization; * Vaccination with live(attenuated) vaccine within 30 days prior to randomization or plan to receive live (attenuated) vaccine during the study; * Are using concomitant medications or treatments that are prohibited in the protocol; * The following laboratory abnormalities occurred during the screening period: eosinophils≥1500 cells/mm3 or 1.5×109/L; Platelets≤80,000 cells/mm3 or 80×109/L; phosphocreatine kinase (CPK) ≥5 times the upper limit of normal (ULN); alanine aminotransferase (ALT) ≥3-fold ULN; aspartate aminotransferase (AST)≥ 3-fold ULN; Bilirubin ≥ 2x ULN; * History of alcohol abuse or drug abuse within 12 months prior to randomization; * Current smokers, or those who have been smoking in recent 6 months, or former smokers who have not been smoking for 6 months with a smoking history of ≥10 pack years; * Allergy to L-histidine, trehalose, or Tween 80, or history of systemic hypersensitivity to any biologic products; * Females of childbearing potential have a positive pregnancy test result during the screening period; Females planning to become pregnant or breastfeeding; * Any clinically significant examination abnormality or serious and/or uncontrolled disease that, in the opinion of the investigator, may affect the subject safety, or affect the evaluation of efficacy, or preclude the subject completion of the entire study.
Conditions Leptomeningeal Metastasis of Breast Canc...
Phase PHASE2
Enrollment 22
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Evaluate the efficacy and safety of Intrathecal Administration of Thiotepa in Combination with Methotrexate via the Ommaya Reservoir in Breast Cancer with Leptomeningeal Metastasis

Design

Study type: Interventional Phases: Phase2 Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Intrathecal Administration of Thiotepa in Combination with Methotrexate via the Ommaya Reservoir — Patients received 15 mg MTX intrathecally combined with 10 mg thiotepa twice a week for 2 weeks (4 injections), followed by a maintenance phase in which the same agents and dosages were administered every three weeks until an event meeting the termination criteria occurs.

Primary Outcomes

  • Intracranial Overall Response Rate (From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2024-08-08
Completion: 2026-12-13
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 22 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: The First Affiliated Hospital with Nanjing Medical University
Collaborators: The Affiliated Brain Hospital of Nanjing Medical University
Contact Information
Study Contact:
Wei Li, Ph.D
025-68307102
real.lw@163.com
Wei Li, Ph.D
25-68307102
real.lw@163.com
Jiangsu Provincial People's Hospital
Wei Li, Ph.D
Jiangsu Provincial People's Hospital
Interventions
  • Drug: Intrathecal Administration of Thiotepa in Combination with Methotrexate via the Ommaya Reservoir — Patients received 15 mg MTX intrathecally combined with 10 mg thiotepa twice a week for 2 weeks (4 injections), followed by a maintenance phase in which the same agents and dosages were administered every three weeks until an event meeting the termination criteria occurs.
Study Locations (1 sites)
Jiangsu Provincial People's Hospital, Nanjing, Jiangsu 210000 China
Eligibility Criteria
Inclusion Criteria: 1. Patient is an adult female ≥18 and ≤75 years old at the time of informed consent. 2. ECGO rating 0-3. 3. Histologically or cytologically confirmed breast cancer. 4. A new diagnosis of LM, established either by the presence of malignant cells in the CSF or by the combination of characteristic clinical manifestations and magnetic resonance imaging (MRI) findings 5. Patients can be implanted or have been implanted with Ommaya reservoirs; 6. Patient must have at least one measurable lesion (according to RECIST 1.1 criteria); 7. Postmenopausal or pre/perimenopausal female patients are eligible for enrolment; pre or perimenopausal female patients must be willing to receive LHRHa during the study period. 8. All patients were required to meet the following laboratory biochemical values prior to enrolment: * Haematology: Hb ≥90 g/L, WBC ≥3.5×109/L, ANC ≥1.5×109/L, PLT ≥100×109/L; * Liver function: for those without liver metastases, AST, ALT, ALP ≤2.5 times the upper limit of normal values, and ≤1.25 x the upper limit of normal values for total bilirubin; for those with liver metastases, AST, ALT, ALP ≤ 5 times the upper limit of normal value, and total bilirubin ≤ 1.5 x upper limit of normal value. Exclusion Criteria: 1. Patients with other malignant tumors, excluding basal cell carcinoma and carcinoma in situ 2. Patients with severe or uncontrolled systemic disease, including uncontrolled hypertension or active bleeding tendency 3. The investigator considers the patient unsuitable for entry into this study. 4. Patients with toxicity from prior therapy that has not returned to normal or NCI-CTCAE grade 5.0 5. Patients who have a drug allergy or metabolic disorder to the drugs in this regimen 6. Pregnant or lactating women (women of childbearing age must have had a negative pregnancy test within 14 days prior to the first dose; if positive, pregnancy must be ruled out by ultrasound). 7. Patients who are concurrently enrolled in other clinical studies
Conditions Heart Failure, Heart Diseases, Cardiovas...
Phase NA
Enrollment 850
Locations 68 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of TEAM-HF IDE clinical trial is to evaluate safety and effectiveness of the HeartMate 3 LVAS compared to guideline directed medical therapy (GDMT) in a population of ambulatory advanced heart failure patients who are not dependent on intravenous inotrope.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Device: CardioMEMS HF System — The CardioMEMS™ HF System is comprised of a lead-less and battery-less pressure sensor which remotely transmits pulmonary artery pressure measurements.
  • Device: HeartMate 3 Left Ventricular Assist System — The HeartMate 3 LVAS is a mechanical circulatory support pump with Full MagLev Technology that assumes some or all of the workload of the left ventricle. The HeartMate 3 LVAS is used in advanced heart failure patients needing short or long-term mechanical circulatory support.
  • Other: Guideline Medical Directed Therapy — Optimal doses of medical therapy per established heart failure guidelines which includes the following stable combination of Beta Blockers, ACE-inhibitors or ARB or ARNi, MRA and SGLT2 inhibitors.

Primary Outcomes

  • Survival at 2 years free of disabling stroke, reoperation to replace the device, or worsening HF requiring listing for urgent heart transplantation or mechanical circulatory support, enrollment into hospice, or dependence on IV inotropes (2 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-12-13
Completion: 2032-09
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 850 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Abbott Medical Devices
Principal Investigators:
  • Kelly O'Connell, PhD (STUDY_DIRECTOR) - Abbott
Contact Information
Study Contact:
Nourdine Chakouri, PhD
925-989-5982
nourdine.chakouri@abbott.com
Abisola Akinbobola
602-857-2052
Abisola.Akinbobola@bannerhealth.com
Banner-University Medical Center Phoenix
Radha Gopalan, MD
Banner-University Medical Center Phoenix
Interventions
  • Device: CardioMEMS HF System — The CardioMEMS™ HF System is comprised of a lead-less and battery-less pressure sensor which remotely transmits pulmonary artery pressure measurements.
  • Device: HeartMate 3 Left Ventricular Assist System — The HeartMate 3 LVAS is a mechanical circulatory support pump with Full MagLev Technology that assumes some or all of the workload of the left ventricle. The HeartMate 3 LVAS is used in advanced heart failure patients needing short or long-term mechanical circulatory support.
  • Other: Guideline Medical Directed Therapy — Optimal doses of medical therapy per established heart failure guidelines which includes the following stable combination of Beta Blockers, ACE-inhibitors or ARB or ARNi, MRA and SGLT2 inhibitors.
Study Locations (68 sites)
Banner-University Medical Center Phoenix, Phoenix, Arizona 85006 United States
Baptist Health Medical Center, Little Rock, Arkansas 72205 United States
Sutter Medical Center, Sacramento, California 95816 United States
University of California at San Francisco, San Francisco, California 94143 United States
Washington Hospital Center, Washington D.C., District of Columbia 20010 United States
Shands at the University of Florida, Gainesville, Florida 32610 United States
Cleveland Clinic Florida, Weston, Florida 33331 United States
Piedmont Heart Institute, Atlanta, Georgia 30309 United States
Piedmont Augusta Hospital, Augusta, Georgia 30901 United States
WellStar Kennestone Hospital, Marietta, Georgia 30060 United States
Eligibility Criteria
Inclusion Criteria: 1. Subject has provided written informed consent by signing the study Informed Consent Form (ICF) prior to any clinical investigation-related procedure 2. LVEF ≤30% and Cardiac Index ≤ 2.5 L/min/m² 3. Limited functional status as demonstrated by 6MWT ≤ 350 m due to HF related reasons OR peak VO2 ≤ 14 mL/kg/min (or \<50% of predicted peak VO2 value) 4. NYHA Class IIIB or NYHA Class IV 5. Subject has ≥ 1 Heart Failure Hospitalization in the last 12 months 6. Subject is already implanted with a CardioMEMS PA Sensor OR willing to undergo a CardioMEMS PA Sensor implant 7. Subject is willing and able to be implanted with the HM3 LVAS if randomized to HM3 Group Randomization Criteria: 1. Subject has been implanted with a CardioMEMS PA Sensor for at least 90 days. 2. Subject is receiving guideline directed medical therapy with optimal doses (or documented medication contraindication or intolerance) of betablockers, Angiotensin-Converting-Enzyme-inhibitors or Angiotensin II Receptor Blockers or angiotensin receptor neprilysin inhibitor (if eligible), Mineralocorticoid Receptor Antagonists, Sodium-Glucose co-Transporter-2 (SGLT2) inhibitors, and diuretics for at least 30 of the last 90 days. 3. mean PAP ≥ 30 mmHg. 4. The subject will not be randomized if they have any other factor that represents inordinate risk for either continued GDMT or LVAD implant. Single Arm Registry Criteria: 1. Subject has received a CardioMEMS PA Sensor implant following enrollment in the trial. 2. Subject is receiving guideline directed medical therapy with optimal doses (or documented medication contraindication or intolerance) of betablockers, Angiotensin-Converting-Enzyme-inhibitors or Angiotensin II Receptor Blockers or angiotensin receptor neprilysin inhibitor (if eligible), Mineralocorticoid Receptor Antagonists, Sodium-Glucose co-Transporter-2 (SGLT2) inhibitors, and diuretics for at least 30 of the last 90 days. 3. mean PAP \<30 mmHg Exclusion Criteria: 1. Subject is \< 18 years of age at the time of informed consent. 2. Dependent on IV inotrope in the last 30 days. 3. Contra-indications to HM3 LVAS or CardioMEMS HF system. 4. Etiology of HF due to or associated with uncorrected thyroid disease, obstructive cardiomyopathy, pericardial disease, amyloidosis, or restrictive cardiomyopathy. 5. Technical obstacles to LVAD or CardioMEMS implantation which pose an inordinately high surgical risk, in the judgment of the implanter. 6. Existence of ongoing MCS. 7. Presence of mechanical aortic valve that will not be either converted to a bioprosthesis or oversewn at the time of LVAD implant. 8. History of any solid organ transplant. 9. Psychiatric disease/disorder, irreversible cognitive dysfunction or psychosocial issues that are likely to impair compliance with the study protocol and LVAS management. 10. Presence of an active, uncontrolled infection. 11. Complex congenital heart disease. 12. Currently Pregnant or capable of becoming Pregnant and Unwilling to Use Contraception with LVAD. 13. History of pulmonary embolism within 30 days prior to enrollment or history of recurrent (\>1 episode) pulmonary embolism and/or deep vein thrombosis. 14. Planned VAD or Bi-VAD support prior to enrollment. 15. Presence of any one of the following risk factors for or indications of severe end organ dysfunction or failure: 1. An INR ≥ 2.0 not due to anticoagulation therapy 2. An eGFR \< 30 mL/min/1.73 m2 and nonresponsive to diuretic therapy or receiving chronic dialysis. 3. Biopsy proven liver cirrhosis. 4. Need for chronic renal replacement therapy. 5. History of severe chronic obstructive pulmonary disease (COPD) defined by Forced Expiratory Volume FEV1 \< 30% predicted. 6. History of cerebrovascular disease with significant (\> 80%) uncorrected internal carotid stenosis. 7. Significant peripheral vascular disease (PVD) accompanied by ischemic rest pain or extremity ulceration. 16. Any condition other than HF that could limit survival to less than 24 months. 17. Participation in any other clinical investigation with an active treatment arm that is likely to confound study results or affect the study outcome.
Conditions Safety, Psychological, Acceptability of ...
Phase NA
Enrollment 50
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This Pilot Randomized Controlled Trial (RCT) overall aim is to establish the safety, feasibility, acceptability and preliminary effects of a body-oriented psychotherapy, Somatic Experiencing (SE), on social functioning and mental health among adults with a history of Child Maltreatment (CM) and symptoms of posttraumatic stress disorder (PTSD) or complex posttraumatic stress disorder (CPTSD). Participants will be randomized either to an SE-group (n=25, psychoeducation, and information about treatment possibilities + 15-session SE treatment) or to a control group (n=25, same psychoeducation and information about treatment possibilities + regular phone calls to provide updates on their well-being and if they started a treatment). Given the lack of research on the effect of SE on Psychological Safety in this population, while SE has not yet been introduced into the Swedish health care system, special consideration will be given to participant safety, feasibility and acceptability of the SE-treatment. This includes monitoring (and assessing) for serious adverse events (SAEs) and adverse events (AEs), if conducting an RCT on SE in our target sample is feasible (e.g., achieving the target sample goal, assessing attrition rates and session attendance) and the acceptance of the used SE intervention (e.g., positive evaluations and willingness to recommend the treatment). Next to assessing safety, feasibility and acceptability, preliminary outcomes (self-report and experimental measures) will be evaluated at pre-treatment, post-treatment (20 weeks after pre), and at a 20-week follow-up, assessing primary outcomes (Psychological Safety) and secondary outcomes (Social Safeness, PTSD, CPTSD, Depression), as well as additional factors (e.g., interoception) that could contribute to decreased mental health and social functioning issues. Additionally, participants' behavioral (e.g., interpersonal distance) and physiological responses (HR, HRV, EDA) to social stimuli will be assessed pre- and post-treatment in an experimental setup to explore SE's potential to reduce Negative Affect and increase Positive Affect (Activated, Relaxed, Safe/Content) in response to social stress.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Single

Interventions / Regimen

  • Behavioral: SE-group — Psychoeducation and information about treatment possibilities + SE-treatment
  • Behavioral: Control — Psychoeducation and information about treatment possibilities + Phone

Primary Outcomes

  • The Neuroception of Psychological Safety Scale (NPSS; Morton et al., 2024) (Pre-treatment, post-treatment (20 weeks after pre-treatment) and follow-up (20-week after post-treatment).)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-09-06
Completion: 2026-11
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 50 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Monique Pfaltz
Collaborators: Stockholm University
Principal Investigators:
  • Monique Pfaltz (PRINCIPAL_INVESTIGATOR) - +46101428300
Contact Information
Study Contact:
Jörgen Lehmivaara
+46722477195
jorgen.lehmivaara@miun.se
Monique Pfaltz
+46101428300
monique.pfaltz@miun.se
Jörgen Lehmivaara
072-247 71 95
jorgen.lehmivaara@miun.se
Mid Sweden university and Stockholm university
Interventions
  • Behavioral: SE-group — Psychoeducation and information about treatment possibilities + SE-treatment
  • Behavioral: Control — Psychoeducation and information about treatment possibilities + Phone
Study Locations (1 sites)
Mid Sweden university and Stockholm university, Stockholm, Stockholm County Sweden
Eligibility Criteria
Inclusion Criteria: * Adults (18 years or older). * Proficiency in Swedish Language. * Access to a computer/internet. * Meeting CTQ-cutoff for CM history (CTQ rating higher than 'none / minimal' in at least one of the subscales according to Bernstein and Fink (1998) (i.e. ≥10 for emotional neglect, ≥ 8 for physical neglect, ≥9 for emotional abuse, ≥8 for physical abuse and ≥6 for sexual abuse). * Meeting at least moderate/severe PTSD or complex PTSD symptoms on the ITQ. * If taking medication, it must have been ongoing for at least 3 months and the dose must have been stable for 1 month. * Signed informed consent provided. Exclusion Criteria: * Participants screen positive for alcohol (AUDIT) or substance abuse (DUDIT). * Psychotic symptoms, ongoing manic episode, acute suicidality. * If ongoing medication has an impact on the physiological data (ECG) recorded during the social paradigms, physiological data will be excluded from the analyses (but not exclusion for the treatment). * Have current (pre-assessment) ongoing psychological treatment focusing on social safeness, PTSD or complex PTSD.
Conditions Breast Cancer, Prostate Cancer, NSCLC, C...
Phase NA
Enrollment 302
Locations 15 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this clinical trial is to evaluate single-fraction metastases-directed SBRT in the broader radiation oncology community and to compare its safety and efficacy profile with the current Standard of Care (SoC) of multiple-fraction SBRT in patients with oligometastatic disease of primary breast, prostate, NSCLC and colorectal cancer having all lesions that will be treated with radical radiotherapy amenable to single-fraction SBRT. The main question/hypothesis this clinical trial aims to answer is: \- Single-fraction SBRT has comparable outcomes as those obtained with multiple fraction SBRT, both in terms of safety and efficacy. Patients from the OligoCare cohort will be randomized to receive either single-fraction SBRT or the current SoC of multiple-fraction SBRT.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Radiation: single-fraction SBRT — Single-fraction SBRT (Stereotactic Body Radiation Therapy) is a precise form of radiation therapy that delivers a high dose of radiation in a single treatment session to a targeted area, often used for treating small, well-defined tumors. This approach minimizes exposure to surrounding healthy tissues while effectively treating the tumor.
  • Radiation: multiple-fraction SBRT — Multiple-fraction SBRT (Stereotactic Body Radiation Therapy) is a precise form of radiation therapy that delivers high doses of radiation over several treatment sessions to a targeted area, typically used for treating small, well-defined tumors. This method helps to further protect surrounding healthy tissues by spreading the total radiation dose over multiple sessions.

Primary Outcomes

  • Grade 3+ SBRT-related toxicity (within 12 months following treatment with radical radiotherapy.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-04-15
Completion: 2029-02-15
Eligibility
Age: Not reported
Sex: ALL
Volunteers: false
Enrollment: 302 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
Principal Investigators:
  • Matthias Guckenberger, MD (PRINCIPAL_INVESTIGATOR) - Radiation Oncology, University of Zurich, Switzerland
  • Piet Ost, MD (PRINCIPAL_INVESTIGATOR) - GZA Sint-Augustinus, Wilrijk, Belgium
Contact Information
Study Contact:
EORTC HQ
+32 2 774 16 11
eortc@eortc.org
Interventions
  • Radiation: single-fraction SBRT — Single-fraction SBRT (Stereotactic Body Radiation Therapy) is a precise form of radiation therapy that delivers a high dose of radiation in a single treatment session to a targeted area, often used for treating small, well-defined tumors. This approach minimizes exposure to surrounding healthy tissues while effectively treating the tumor.
  • Radiation: multiple-fraction SBRT — Multiple-fraction SBRT (Stereotactic Body Radiation Therapy) is a precise form of radiation therapy that delivers high doses of radiation over several treatment sessions to a targeted area, typically used for treating small, well-defined tumors. This method helps to further protect surrounding healthy tissues by spreading the total radiation dose over multiple sessions.
Study Locations (15 sites)
Onze Lieve Vrouw Ziekenhuis, Aalst, Belgium
Institut Jules Bordet, Brussels, Belgium
Universitair Ziekenhuis Gent, Ghent, Belgium
AZ Groeninge Kortrijk, Kortrijk, Belgium
Ziekenhuis aan de Stroom (ZAS) - ZAS Augustinus, Wilrijk, Belgium
Azienda Ospedaliero-Universitaria Careggi, Florence, Italy
Istituto Clinico Humanitas, Milan, Italy
Istituto Europeo di Oncologia, Milan, Italy
Sacro Cuore Hospital, Negrar, Italy
Policlinico Universitario Campus Bio-Medico- Oncology Center, Roma, Italy
Eligibility Criteria
Inclusion Criteria: * Patient is part of the RP1822-OligoCare. As in OligoCare, ALL active cancer lesions (loco-regional primary and all oligometastases) were or will be treated with radical intent (surgery or radiotherapy). * All lesions that will be treated with radical radiotherapy have to be amenable to single-fraction SBRT. Concurrent systemic treatment is allowed. * Written informed consent must be given according to ICH/GCP, and national/local regulations. Patients will be consented in a step-wise approach. Step 1 \[both control and experimental arms\]: patients will need to consent to be included and evaluated in E²-RADIatE (that includes the non-interventional OligoCare prospective registry cohort) and to potentially be randomized to future sub-studies for which they are eligible; no further consent will be sought if they are randomized to the SoC (control) arm; Step 2 \[experimental arm only\]: if eligible for the current sub-study and randomized to receive single-fraction SBRT, patients will need to consent to receiving the experimental treatment. Exclusion Criteria: All targeted lesion judged by the treating physician to be associated with risks for severe toxicity following single-fraction SBRT. The following lesions are systematically excluded: * Pulmonary metastases within 1 cm of proximal bronchial tree, esophagus or brachial plexus * Metastases within \< 5 mm of any hollow GI structure: esophagus, stomach, small bowel, large bowel * Metastases within \< 5 mm of the spinal cord, the cauda equina or the brachial plexus * Metastases \> 5 cm in largest diameter.
Conditions Interoception, Pulmonary Hypertension
Phase NA
Enrollment 32
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Background Pulmonary hypertension is a rare and incurable condition characterised by fatigue and breathlessness. The effects of pulmonary hypertension has a significant impact on an individual's emotional wellbeing and there are currently no established psychological interventions to improve this. Interoception is defined as the ability to perceive the internal state of the body and emerging research suggests that interventions to improve interoception can improve well-being. Aims The project aims to develop an interoceptive based intervention for those with pulmonary hypertension and examine the feasibility and acceptability of this. Additional aims are to explore the preliminary results of the intervention. Methods A randomised control feasibility trial will be used. Thirty-two participants will be included. Participants will be patients within the Scottish Pulmonary Vascular Unit diagnosed with pulmonary hypertension and randomly assigned to either the intervention or control (waitlist) group. The intervention will be an eight-session online group and participants will complete measures for interoception, anxiety, depression, health related quality of life, as well as a feasibility and acceptability questionnaire. Quantitative analysis will include descriptive statistics and T-tests (including non-parametric versions) to analyse the feasibility and gain a preliminary understanding of the intervention. Practical Applications It is hoped that the findings will identify a sample size for a larger trial whilst also informing future clinical practice. This project will be written up for a suitable journal and will be presented at an appropriate conference.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Supportive Care Masking/blinding: None

Interventions / Regimen

  • Other: interoceptive group based intervention — 8 week online group intervention aiming to improve interoception.

Primary Outcomes

  • Multidimensional Assessment of Interoceptive Awareness (MAIA-2) (baseline (up to 4 weeks prior to intervention starting) and 8 weeks (during last intervention session))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-06-17
Completion: 2025-10-18
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 32 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Golden Jubilee National Hospital
Contact Information
Study Contact:
Derick Moore
+44 07805511803
2021489m@student.gla.ac.uk
Lynne Johnston, Doctorate Clinical Psychology
lynne.johnston4@gjnh.scot.nhs.uk
Joanne McGarry
joanne.mcgarry@gjnh.scot.nhs.uk
Golden Jubilee National Hospital
Interventions
  • Other: interoceptive group based intervention — 8 week online group intervention aiming to improve interoception.
Study Locations (1 sites)
Golden Jubilee National Hospital, Glasgow, Clydebank g81 4dy United Kingdom
Eligibility Criteria
Inclusion Criteria: * Participants will be patients under the care of the Scottish Pulmonary Vascular Unit (SPVU) at the Golden Jubilee University National Hospital (GJUNH). * Diagnosed with any type of PH. * Adults over 18 years. * Fluent in English. * Able to commit to the duration of the research (expected to be three months from initial recruitment to the end of treatment). Exclusion Criteria: * Individuals with current thoughts of self-harm or suicide. * Presenting with comorbid alcohol or substance misuse. * Currently engaging in any additional psychological interventions at the time of the study.
Conditions Triple-Negative Breast Cancer
Phase PHASE2
Enrollment 160
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This study is a Phase 2, open-label,multicenter study designed to evaluate the efficacy and safety of 9MW2821monotherapy or combined with PD-1 inhibitor in locally advanced or metastatic Triple-Negative Breast Cancer.

Design

Study type: Interventional Phases: Phase2 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: 9MW2821 — Subjects will receive intravenous (IV) infusion of 9MW2821 as per protocol
  • Drug: PD-1 inhibitior — Subjects will receive intravenous (IV) infusion of PD-1 inhibitor as per protocol

Primary Outcomes

  • Objective Response Rate (Up to 24 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2024-07-26
Completion: 2027-07
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 160 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Mabwell (Shanghai) Bioscience Co., Ltd.
Contact Information
Study Contact:
Jian Zhang, Professor
13918273761
syner2000@163.com
Jian Zhang, Professor
syner2000@163.com
Fudan University Shanghai Cancer Center
Jian Zhang, Professor
Fudan University Shanghai Cancer Center
Interventions
  • Drug: 9MW2821 — Subjects will receive intravenous (IV) infusion of 9MW2821 as per protocol
  • Drug: PD-1 inhibitior — Subjects will receive intravenous (IV) infusion of PD-1 inhibitor as per protocol
Study Locations (1 sites)
Fudan University Shanghai Cancer Center, Shanghai, Shanghai Municipality 200032 China
Eligibility Criteria
Inclusion Criteria: 1. Competent to comprehend, sign, and date an independent ethics committee/institutional review board/research ethics board (IEC/IRB/REB) approved informed consent form. 2. Male or female subjects aged 18 to 75 years (including 18 and 75 years). 3. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. 4. Histopathological diagnosed of locally advanced or metastatic triple negative breast cancer. Not suitable for radical therapy. 5. Subjects who have failed standard treatment or naive to systemic antitumor therapy in advanced setting. 6. Subjects must submit tumor tissues for test. 7. Life expectancy of ≥ 12 weeks. 8. Subjects must have measurable disease according to RECIST (version 1.1). 9. Adequate organ functions. 10. Sexually active fertile subjects, and their partners, must agree to use methods of contraception during the study and at least 6 months after termination of study therapy. 11. Subjects are willing to follow study procedures Exclusion Criteria: 1. Preexisting treatment related toxicity Grade ≥ 2 and Grade ≥ 3 immune related adverse reactions 2. Preexisting peripheral neuropathy Grade ≥ 2. 3. Hemoglobin A1C (HbA1c) ≥ 8%. 4. Has ocular conditions that may increase the risk of corneal epithelium damage. 5. History of ILD or pneumotitis, other severe or uncontrolled disease or central nervous system metastases. 6. Chemotherapy or radiotherapy within 21 days prior to the first dose of study drug (Cohort A). Received immune checkpoint inhibitor or systemic immunosuppressive therapy was administered within 14 days prior to the first study (Cohort B and C). traditional Chinese medicine with anticancer indication within 14 days prior to the first dose of study drug, use of any investigational drug or device within 28 days prior to the first dose of study drug, received treatment of nectin-4 targeted ADC with MMAE payload, any P-glycoprotein (P-gp) inducers/inhibitors or strong CYP3A4 inducers/inhibitors within 14 days prior to the first dose of study drug, major surgery within 28 days prior to first dose of study drug or any live vaccines within 28 days before first dose of study drug or during the study.. 7. History of allogeneic hematopoietic stem cell transplantation or solid organ transplantation; 8. Known sensitivity to any of the ingredients of the investigational product; History of drug abuse or mental illness. 9. Documented history of pulmonary embolism or clinically significant cardiac or cerebrovascular diseases within 6 months prior to the first dose of study drug 10. Active autoimmune disease requiring systemic treatment within 2 years before the subject's first study medication. 11. History of another malignancy within 3 years before the first dose of study drug. 12. Not suitable to receive study treatment for other conditions as per investigator.